Skp2 Inhibitor C1

Cat. No.:	HY-16661
CAS No.:	432001-69-9
Molecular Formula:	$C_{18}H_{13}BrN_2O_4S_2$
Molecular Weight:	465.34
Target:	E1/E2/E3 Enzyme
Pathway:	Metabolic Enzyme/Protease
Storage:	Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year



SOLVENT & SOLUBILITY

In Vitro

DMSO : 20.83 mg/mL (44.76 mM; Need ultrasonic)

Preparing Stock Solutions	Mass / Solvent / Concentration	1 mg	5 mg	10 mg
	1 mM	2.1490 mL	10.7448 mL	21.4897 mL
	5 mM	0.4298 mL	2.1490 mL	4.2979 mL
	10 mM	0.2149 mL	1.0745 mL	2.1490 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

1. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)
   Solubility: ≥ 2.08 mg/mL (4.47 mM); Clear solution

BIOLOGICAL ACTIVITY

Description

Skp2 Inhibitor C1 (SKPin C1) is an S-phase kinase-related protein 2 (Skp2) inhibitor with an inhibitory effect on metastatic melanoma cells. Skp2 Inhibitor C1 slows the cell cycle, inhibits cell proliferation, and triggers apoptosis[1].

In Vitro

Skp2 Inhibitor C1 (10-50 μM; 12 hr) decreases the viability of THP-1, U266 and RPMI 8226 cells[1].
Skp2 Inhibitor C1 (25 μM) increases p27 protein levels in U266 and RPMI 8226 cells by inhibiting ubiquitination[1].
Skp2 Inhibitor C1 (25 μM) inhibits cell cycle of U266 and RPMI 8226 cells[1].
MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Cycle Analysis[1]

Cell Line:	B lymphocytes, THP-1, U266 and RPMI 8226 cells
Concentration:	0, 5, 10, 25, and 50 μM

Incubation Time:	12 hr, 24 hr, 36 hr, and 48 hr
Result:	Significantly decreased the viability of U266 and RPMI 8226 cells at 10 μM for 12 hours. Did not significantly affect B lymphocyte viability at 50 μM. Decreased THP-1 cell viability at 50 μM for 12 hours.

Cell Viability Assay[1]

Cell Line:	U266 and RPMI 8226 cells
Concentration:	0, 5, 10, 25, and 50 μM
Incubation Time:	12 hr
Result:	Increased the percentages of U266 and RPMI 8226 cells in the G0/G1 phase, while decreased the percentages in S and G2/M phases.

In Vivo

Skp2 Inhibitor C1 (5 mg/kg and 10 mg/kg; 3 times within 24 h: 24, 5, and 1 h before the test) shows the antidepressant-like effect in mouse models following chronic treatment by using the tail suspension test (TST), forced swimming test (FST), and social interaction test (SIT)[2].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

CUSTOMER VALIDATION

- Leukemia. 2020 May;34(5):1241-1252.
- Int Immunopharmacol. 2023 Jun 9;121:110452.
- Transl Oncol. 2020 Oct;13(10):100809.
- Neoplasia. 2023 Mar 3;38:100890.
- Oncol Rep. 2016 Jul;36(1):559-66.

See more customer validations on www.MedChemExpress.com

REFERENCES

[1]. Yang Y, et al. Skp2 inhibitor SKPin C1 decreased viability and proliferation of multiple myeloma cells and induced apoptosis. Braz J Med Biol Res. 2019;52(5):e8412.

[2]. Li F, et al. Identification of the antidepressive properties of C1, a specific inhibitor of Skp2, in mice. Behav Pharmacol. 2021 Feb 1;32(1):62-72.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA